A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303

Trial Profile

A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Amiselimod (Primary) ; Fingolimod
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 06 Dec 2016 Results assessing cardiac safety profile published in the British Journal of Clinical Pharmacology (2016).
    • 19 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top